Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancerReportar como inadecuado

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 7, pp 961–967

First Online: 24 December 2008Received: 14 October 2008Accepted: 04 December 2008


PurposeTo evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer HNSCC.

Methods and patientsFrom October 2003 to October 2006, 50 patients with HNSCC stage III-IVA-IVB were treated. In 32 patients, surgery and adjuvant radiotherapy64 Gy, in 18 patients definitive radiotherapy70 Gy was performed. Low-dose-cisplatin was applied concomitantly 6 mg-m-every radiotherapy-day.

ResultsAcute toxicity ≥grade 3 was observed in 22 patients 11 patients mucositis-dysphagia, 7 hematologic toxicity, 4 mucositis-dysphagia-hematologic toxicity. 90% of our patients received >80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity ≥grade 3 xerostomia, subcutaneous fibrosis, or lymphedema was observed in nine patients.

ConclusionWe found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials.

KeywordsLow dose cisplatin HNSCC Radiochemotherapy Toxicity  Download fulltext PDF

Autor: Hendrik Andreas Wolff - Tobias Overbeck - Ralph M. Roedel - Robert M. Hermann - Markus K. A. Herrmann - Tereza Kertesz


Documentos relacionados